Tracking VZV Across the Lifespan and the Role of Sensitive Detection

Primary varicella: the infection that never leaves

VZV enters through the respiratory tract, spreads via a first viremia to lymphoid tissue, then a second viremia that seeds the skin and the sensory ganglia. Chickenpox is typically mild in healthy children but can be severe in adults, in whom pneumonia and hepatitis are more common, and in the immunocompromised, where disseminated disease can be life-threatening. After the rash resolves, the virus does not disappear: it travels retrograde along sensory axons to establish latency in the dorsal root and cranial nerve ganglia, where its genome persists in a quiet, non-replicating state for the rest of the person's life.

This latency is the hinge of VZV biology. It is why a disease of childhood predicts a disease of old age, and why nearly every adult is a potential future shingles case. The lifetime risk of herpes zoster sits near one in three in the general population, climbing toward one in two for long-lived adults. Primary varicella is therefore never just a pediatric event; it is the first chapter of a lifelong narrative.

Vaccine gaps, breakthrough infection, and shifting epidemiology

Childhood varicella vaccination has sharply cut chickenpox incidence and severe outcomes where adopted, but it has also altered the VZV landscape. Natural boosting from contact with infected children helps maintain adult VZV immunity; as wild-type exposure falls, several surveillance systems have noted shifts in shingles incidence that vary by age and setting. A Japanese study of universal varicella vaccination and pandemic-era behavior change found herpes zoster incidence continued to climb across age groups, underscoring that vaccination alone does not remove the underlying age-related risk.

On the other side, recombinant zoster vaccines for older and immunocompromised adults are highly effective, yet breakthrough cases still occur — and they are informative. Analysis of three randomized trials showed the recombinant zoster vaccine reduced both the duration of clinically significant pain and the use of pain medication even in vaccinated people who developed breakthrough shingles, while real-world US claims data show vaccine uptake remains low: only about 9% of adults 50 and older had received two doses in recent years. The gap between proven prevention and population coverage is itself a research and surveillance target, and understanding breakthrough disease depends on laboratory confirmation that a rash really is VZV.

Telling VZV apart from HSV and other rash illnesses

Clinically, shingles can be confused with herpes simplex virus (HSV) recurrence, contact dermatitis, impetigo, and, increasingly, the vesicular rashes of emerging infections. The old Tzanck smear, which shows multinucleated giant cells, cannot separate VZV from HSV at all. This is why molecular testing became the reference standard: a single swab can simultaneously interrogate HSV-1, HSV-2, and VZV, removing guesswork. In the 2022 mpox outbreak, the overlap between mpox, HSV, and VZV lesions pushed clinics toward multiplex vesicular panels that detect all three from one specimen — a clear illustration of how differentiation drives both diagnosis and surveillance.

For CSF and other sterile sites, distinguishing VZV from HSV and from enteroviruses matters enormously for therapy and prognosis. PCR on cerebrospinal fluid is the front-line test for VZV CNS infection, especially because some VZV syndromes present without rash. When PCR is negative but suspicion remains, an antibody index demonstrating intrathecal anti-VZV synthesis can be the deciding evidence, particularly in vasculopathy. The lesson for researchers is that no single target suffices; robust panels and validated controls are essential.

Figure 2. Comparison of the assay in a single-plex and multiplex approach. (Source: Luzius T, et al. 2025)

Recombinant antigens and antibodies as research tools

Discovery and surveillance lean on recombinant VZV proteins and research-grade antibodies. Recombinant VZV glycoprotein antigens, above all glycoprotein E, standardize ELISAs, coat capture-assay surfaces, and probe the specificity of sera in vaccine studies. Research-grade anti-VZV antibodies serve as detection and confirmatory reagents in immunohistochemistry, Western blotting, and lateral-flow development, and as positive controls proving an assay works. They are not therapies but the instruments that let scientists watch VZV across the lifespan — from a child's first rash through maternal-fetal transmission to the elderly nerve.

As varicella programs mature and zoster vaccines roll out, the need for comparable, reproducible reagents grows. Comparing incidence between countries, monitoring breakthrough disease, and evaluating next-generation vaccines all require reagents calibrated to the same viral targets. Investment in well-characterized recombinant antigens and antibodies is, in effect, investment in the quality of every epidemiology number we report.